The pharmacokinetics of metronidazole was determined after a single intramuscular (i.m.) dose of 30 mg⋅kg -1 -body weight in five camels, sheep and goats. Marked differences were found between the three species in some of the kinetic parameters. For example, the elimination half-lives (t 1/2 ; h) in camels, sheep and goats were 10.0, 6.21 and 5.87, respectively. The drug maximum concentrations in plasma, C max (mg⋅ml -1 ), were 28.3, 54.6 and 54.4 in camels, sheep and goats, respectively. The time to reach C max , t max (h), were 5, 4 and 2 in camels, sheep and goats, respectively. The mean residence times (MRT; h) in camels, sheep and goats were 16.7, 10.8 and 8.64, respectively. In the light of the present kinetic data and known microbial sensitivities of metronidazole, we recommend an i.m. dose of 15 mg⋅kg -1 in camels and 10 mg⋅kg -1 in sheep and goats, every 12 h.
480 and 600 min. Blood was centrifuged at 900 g for 10 min at 5 o C, and the harvested plasma was immediately stored at -70 0 C until analysed.
Drug analysis
Plasma samples were assayed for metronidazole concentration using a high performance liquid chromatographic (HPLC) method (Neff -Davis et al. 1981 ) with minor modifications. Briefly, reverse-phase separations were developed (Whatman Partisil 10 column, ODS-2 bonded packing, 10 µm particles, 4.6 mm i.d. × 250 mm) using a mobile phase of 65% v/v methanol in 0.01 M acetate buffer, pumped at 63 ml⋅h -1 . . Detection was at 254 nm. Caffeine was employed as the internal standard to minimise errors from volume changes. The retention times for metronidazole and caffeine were 3.7 min and 5.4 min, respectively. Recovery of metronidazole following extraction from camel, sheep and goat plasma was 90.9 ± 11.8%, 88.5 ± 7.1% and 68.4 ± 12.8% (n = 6 experiments), respectively. Calibrations for each species were prepared by supplementing drug-free plasma with metronidazole. Duplicate analyses were performed. The minimum quantifiable concentration of the assay was 0.05 mg⋅l -1 . Intra-and inter-assay coefficients of variation were less than 10% over the working concentration range of 0.1-2.5 mg⋅l -1 .
Kinetic analysis
The maximum plasma concentration (C max ) and the time (t max ) to reach the C max were obtained by inspection of the raw data. The elimination rate constant (K el ) was represented by the slope of the terminal phase following leastsquares fitting of the post-peak plasma concentration-time data, from which was calculated the terminal half-life (t 1/2 = 0.693 / K). Areas under the metronidazole plasma concentration-time curve extrapolated to infinite time (AUC 0-∞ ) were calculated using log-trapezoidal integration. Calculation of the pharmacokinetic parameters was performed using a non-compartmental approach (Rowland and Tozer 1995a) ; the systemic clearance, (Cl/F), and the apparent steady-state volume of distribution (V ss /F), both corrected for fraction (F) of the absorbed dose, were calculated as follows:
where D is the metronidazole dose, AUMC 0-is the area under the first moment metronidazole plasma concentration-time curve, extrapolated to infinite time, and MRT is the mean residence time of metronidazole in the body from the time of administration to its elimination.
Statistics
Statistical hypothesis testing on t 1/2 values were performed using the MINITAB for Windows package (release 12.1, Minitab Inc., State College, PA, USA). Pharmacokinetic parameter values were expressed as the mean ± SD, except t max , which was recorded as the median. Testing for normality was conducted using the Anderson-Darling statistic (D 'Agostino and Stephens 1986) . Species differences in t 1/2 were compared by means of one-way analysis of variance. Posthoc, pairwise comparisons of mean t 1/2 values (camel:goat, camel:sheep, sheep:goat) were analyzed by Duncan's multiple range test (Dunnett and Goldsmith 1994) . The significance level (P) was set to 0.05 in all statistical analyses. Table 1 . The C max (mg/ml) and t max (h) of the drug in camels (28.3 and 5), were markedly different from that in sheep (54.6 and 4) and goats (54.4 and 2). The t 1/2 values were drawn from a distribution which did not deviate significantly from normal (Anderson- 
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Darling A-squared value = 0.463, P > 0.05). Although there were no statistically significant differences (P > 0.05) among the mean T 1/2 values for the 3 species, or between-species pairs of means (P > 0.05), there appeared to be noticeable differences in this parameter among the three species (camels: 10.0 h; sheep: 6.21 h; and goats 5.87 h). Comparison of the Twith previously reported values in other animals and humans is shown in Table 2 .
Discussion
No previous data existed for the i.m. administration of metronidazole in animals. A noncompartmental analysis was used because of the erratic absorption of metronidazole from the i.m. site into the bloodstream. In camels, the overall rate of absorption from the muscles into the main circulation appeared to be less than in sheep and goats, as seen in the plasma concentration-time plots. In one of our recent studies (Ali et al. 1998) less than threequarters of the i.m. dose of furosemide was systemically absorbed in camels from a site anatomically similar to that used in the present study. Low and variable i.m. absorption is well known from many human studies on other drugs, and is considered to be due mostly to variability in regional blood flow (Gibaldi 1991) .
There was considerable inter-individual variability in all pharmacokinetic values, for each species. Since only single-dose i.m metronidazole was given, hypothesis testing for species differences in pharmacokinetics was limited because of the possible confounding influence of the unknown systemic i.m. bioavailability. However, assuming that V ss and Cl were independent of the dose, the t 1/2 in camels, sheep and goats can be compared. The mean t _ did not differ significantly among the three species, although the small number of animals per group (n = 5) coupled with appreciable variability (pooled SD = 5.5 h) resulted in a statistical power of only 17%. Further sample size calculations indicated that 29 animals of each species would be required to show a significant difference in t _ with an 80% power. Nonetheless, marked differences in the kinetic parameters among the three species indicated that the camels absorbed and eliminated metronidazole at a rate slower than that seen in sheep or goats. This is in line with previous studies using other probe drugs such as antipyrine.
In humans, metronidazole is converted to several metabolites (Stambaugh et al. 1968; Loft et al. 1986) , and some of these may be active. However, in the present study we did not (for technical reasons) measure plasma concentrations of metabolites in treated animals. Kinetic differences between the three species may not be limited to the parent drug but may also include the metabolic pathways and the relative amounts of the different metabolites of the parent drug. For example, differences between camels and goats in the metabolism of paracetamol (acetaminophen) were reported by some of us previously (Ali et al. 1996) .
Dose recommendations for the use of i.m. metronidazole in camels, sheep and goats can be made in light of the present pharmacokinetic data, and known antimicrobial sensitivities. For metronidazole, the minimum inhibitory concentration for 90% of clinical isolates tested (MIC 90 ) was 2 mg⋅l -1 for most Gram-negative anaerobes such as Bacteroides species, and 4 mg⋅l -1 for Gram-positive anaerobic bacteria such as Clostridium species (Prescott and Baggot 1993) . Therefore, using standard pharmacokinetic formulae for the accumulation of drug concentrations to steady-state (Rowland and Tozer 1995b) , we determined that average concentrations, peak concentrations and trough concentrations of 12 mg⋅l -1 , 22 mg⋅l -1 , and 6 mg⋅l -1 , respectively, should be obtained in plasma at steady-state during 12-hourly i.m. administration of 15 mg⋅kg -1 in camels, and 10 mg⋅kg -1 in sheep and goats.
Further experiments to study the kinetics and bioavailability of metronidazole given by different routes and using a larger number of animals than has been used here, are warranted.
Srovnání farmakokinetiky metronidazolu u velbloudÛ, ovcí a koz
Farmakokinetika metronidazolu byla stanovena po jediném intramuskulárním podání dávky 30 mg⋅kg -1 Ï. h. skupinám velbloudÛ, ovcí a koz, ãítajícím po pûti jedincích. Mezi tûmito tfiemi druhy byly nalezeny znaãné rozdíly nûkter˘ch kinetick˘ch ukazatelÛ, napfi. poloãas vylouãení (t 1/2 h) u velbloudÛ, ovcí a koz byl 10,0, 6,21 a 5, 87 hodin. Maximální koncentrace léku v krevní plazmû, C max (mg⋅ml -1 ) byly 28,3, 54,6 a 54,4 h u velbloudÛ, ovcí a koz. âas potfiebn˘ k dosaÏení maximální koncentrace léku byl 5, 4 a 2 h. Na základû kinetick˘ch údajÛ a známé mikrobiální sensitivity metronidazolu autofii doporuãují i.m. dávky 15 mg⋅kg -1 u velbloudÛ a dávku 10 mg⋅kg -1 u ovcí a koz kaÏd˘ch 12 hodin.
